MAZE THERAPEUTICS, INC. Operating Cash Flow
MAZE THERAPEUTICS, INC. (MAZE) reported Operating Cash Flow of -$54.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.05M.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$39.11M.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$27.73M.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$24.64M.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$111.94M, a 247.38% decline from fiscal 2024.
- MAZE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was $75.95M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$54.17M 10-Q · filed 2026-08-11 | -$81.90M derived: sum of 3 quarters · filed 2026-08-11 | -$106.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$39.11M 10-Q · filed 2026-05-12 | -$66.84M derived: sum of 2 quarters · filed 2026-05-12 | -$91.48M derived: sum of 3 quarters · filed 2026-05-12 | -$121.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$27.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$52.37M derived: sum of 2 quarters · filed 2026-03-25 | -$82.42M derived: sum of 3 quarters · filed 2026-08-11 | -$111.94M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$24.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$54.69M derived: sum of 2 quarters · filed 2026-08-11 | -$84.21M 10-Q · filed 2025-11-06 | -$106.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$30.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$59.57M 10-Q · filed 2026-08-11 | -$82.02M derived: sum of 3 quarters · filed 2026-08-11 | -$105.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$29.52M 10-Q · filed 2026-05-12 | -$51.97M derived: sum of 2 quarters · filed 2026-05-12 | -$75.17M derived: sum of 3 quarters · filed 2026-05-12 | $69.88M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$22.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$45.66M derived: sum of 2 quarters · filed 2026-03-25 | $99.39M derived: sum of 3 quarters · filed 2026-03-25 | $75.95M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$23.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $121.84M derived: sum of 2 quarters · filed 2025-11-06 | $98.41M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $145.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $121.61M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$23.44M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |